BioIVT is a provider of mission critical biological specimens for the pharmaceutical discovery and development market. The Company specializes in control and disease state samples, including tissues, immune cell products, blood, and other biofluids. BioIVT’s portfolio of clinical specimens directly supports precision medicine research and the effort to improve patient outcomes by coupling comprehensive clinical data with donor samples.
© 2026 Linden LLC. All rights reserved.
© 2026 Linden LLC. All rights reserved.
Location: United States, New York, Westbury
Employees: 201-500
Founded date: 2013
Investors 4
| Date | Name | Website |
| 24.08.2026 | Linden Cap... | lindenllc.... |
| - | Thompson S... | tscp.com |
| - | Linden Cap... | linden.com... |
| - | Northstar ... | northstarc... |
Mentions in press and media 17
| Date | Title | Description |
| 02.02.2026 | BioIVT Appoints Dr. Auro Nair as Chief Executive Officer | Woodbury, New York (February 2, 2026) – BioIVT, a leading provider of mission-critical biological specimens for the pharmaceutical research and development and diagnostic markets, today announced that Dr. Auro Nair has been appointed as its... |
| 13.08.2025 | Fix AI Agent Mistakes With Rubrik’s Agent Rewind | Image: Rubrik AI agents are finding their way into business workflows, but they’re not infallible. When these autonomous systems make wrong moves, the damage can be swift and hard to reverse. Data security company Rubrik claims to have a fi... |
| 02.05.2025 | Linden Capital Partners Welcomes Dr. Auro Nair as Operating Partner | Chicago, Illinois (May 2, 2025) – Linden Capital Partners (“Linden”), a Chicago-based private equity firm focused exclusively on healthcare, today announced that Dr. Auro Nair has joined the firm as an Operating Partner. Dr. Nair brings mor... |
| 21.08.2024 | BioIVT Acquires ZenBio Inc.: Supporting Advancements in Drug Discovery and Cosmetics | Combined expertise in primary cell and exosome isolation, skin products and services will advance global research BALTIMORE, Aug. 21, 2024 /PRNewswire/ -- BioIVT, a global research partner and biospecimen solutions provider for drug and dia... |
| 21.08.2024 | BioIVT Acquires ZenBio | BioIVT, a Baltimore, MD-based research partner and biospecimen solutions provider for drug and diagnostic development, acquired ZenBio, a Durham, NC-based company which specializes in advanced cell products and services. The amount of the d... |
| 30.07.2024 | BioIVT Appoints Dr. Judith Dunn and Dr. Auro Nair to its Board of Directors | WESTBURY, N.Y., July 30, 2024 /PRNewswire/ -- BioIVT, a global research partner and biospecimen solutions provider for drug and diagnostic development, today announced the appointment of Dr. Judith Dunn and Dr. Auro Nair to its Board of Dir... |
| 25.07.2024 | BioIVT to Highlight its Integral Role in Drug and Diagnostic Discovery and Development in addition to Neuroscience Research at Premier Life Science Events | Next week BioIVT will attend the Association for Diagnostics & Laboratory Medicine (ADLM) annual meeting and the Alzheimer's Association International Conference (AAIC) WESTBURY, N.Y., July 25, 2024 /PRNewswire/ -- BioIVT, a global rese... |
| 06.05.2024 | BioIVT Highlights its Focus on Cell and Gene Therapy in Spring Industry Events | BioIVT personnel attend the American Society of Gene and Cell Therapy and the International Society of Cell and Gene Therapy Annual Meetings to share how BioIVT can support CGT research from discovery to commercialization WESTBURY, N.Y., Ma... |
| 04.04.2024 | BioIVT to Participate at the American Association for Cancer Research Annual Meeting 2024 | WESTBURY, N.Y., April 4, 2024 /PRNewswire/ -- BioIVT, a global research partner and biospecimen solutions provider for drug and diagnostic development, today announced its presence as an exhibitor at the 2024 American Association for Cancer... |
| 09.08.2023 | ADME and Drug-Drug Interaction Considerations During Drug Development, Upcoming Webinar Hosted by Xtalks | Xtalks Life Science Webinars Understanding the ADME properties and DDI risks of a compound avoids unnecessary clinical studies, costs, delays and more. TORONTO (PRWEB) August 09, 2023 In vitro ADME and drug-drug interaction (DDI) investigat... |
Show more